| Stent thrombosis
Kengreal vs Brilinta
Side-by-side clinical, coverage, and cost comparison for stent thrombosis.Deep comparison between: Kengreal vs Brilinta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBrilinta has a higher rate of injection site reactions vs Kengreal based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Brilinta but not Kengreal, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kengreal
Brilinta
At A Glance
IV infusion
P2Y12 platelet receptor inhibitor
Oral
Twice daily
P2Y12 platelet inhibitor
Indications
- Periprocedural myocardial infarction
- Stent thrombosis
- Coronary Restenosis
- Acute Coronary Syndrome
- Myocardial Infarction
- Coronary Artery Disease
- Acute Ischemic Stroke
- Transient Ischemic Attack
- Stent thrombosis
Dosing
Periprocedural myocardial infarction, Stent thrombosis, Coronary Restenosis 30 mcg/kg IV bolus prior to PCI followed immediately by 4 mcg/kg/min IV infusion for at least 2 hours or duration of procedure, whichever is longer; transition to an oral P2Y12 inhibitor after discontinuation.
Acute Coronary Syndrome, Myocardial Infarction, Stent thrombosis 180 mg oral loading dose, then 90 mg twice daily for the first year; after one year, 60 mg twice daily; use with aspirin 75-100 mg daily.
Coronary Artery Disease 60 mg twice daily; use with aspirin 75-100 mg daily.
Acute Ischemic Stroke, Transient Ischemic Attack 180 mg loading dose, then 90 mg twice daily for up to 30 days; use with aspirin 300-325 mg loading dose and 75-100 mg daily maintenance.
Contraindications
- Significant active bleeding
- Known hypersensitivity to KENGREAL or any component of the product
- History of intracranial hemorrhage
- Active pathological bleeding (e.g., peptic ulcer or intracranial hemorrhage)
- Hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product
Adverse Reactions
Most common Bleeding (GUSTO and TIMI categories), dyspnea
Serious Anaphylactic reactions, anaphylactic shock, bronchospasm, angioedema, stridor, worsening renal function in patients with severe renal impairment
Most common (>=4%) Dyspnea, dizziness, nausea, bleeding
Serious Major bleeding, fatal/life-threatening bleeding, intracranial hemorrhage, bradycardia, ventricular pauses
Postmarketing Thrombotic Thrombocytopenic Purpura, hypersensitivity reactions including angioedema, central sleep apnea, Cheyne-Stokes respiration, rash
Pharmacology
Cangrelor is a direct P2Y12 platelet receptor inhibitor that selectively and reversibly binds the P2Y12 receptor to block ADP-induced platelet activation and aggregation; platelet inhibition occurs within 2 minutes of IV bolus administration and platelet function returns to normal within 1 hour of infusion discontinuation.
P2Y12 platelet inhibitor; ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation, with ticagrelor and its active metabolite being approximately equipotent.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kengreal
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Brilinta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (3/12) · Qty limit (9/12)
UnitedHealthcare
Kengreal
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Brilinta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Kengreal
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Brilinta
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Kengreal.
No savings programs available for Brilinta.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KengrealView full Kengreal profile
BrilintaView full Brilinta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.